Australia Markets closed

Genmab A/S (GMAB)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
37.70+2.01 (+5.63%)
At close: 04:00PM EDT
37.25 -0.45 (-1.19%)
After hours: 04:06PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close35.69
Bid0.00 x 800
Ask0.00 x 1200
Day's range37.30 - 38.17
52-week range26.19 - 49.07
Avg. volume656,450
Market cap24.794B
Beta (5Y monthly)0.60
PE ratio (TTM)57.03
EPS (TTM)0.66
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est40.70
  • Motley Fool

    Genmab A/S (GMAB) Q2 2022 Earnings Call Transcript

    Genmab is not under any obligation to update statements regarding the future, nor to confirm such statements in relation to actual results, unless this is required by law. Please also note that Genmab may hold your personal data as indicated by you as part of our Investor Relations outreach activities in order to update you on Genmab going forward. Please refer to our website for more information on Genmab and our privacy policy.

  • GlobeNewswire

    Genmab Announces Financial Results for the First Half of 2022

    August 10, 2022 Copenhagen, Denmark; Interim Report for the First Six Months Ended June 30, 2022 Highlights Genmab and AbbVie Inc. (AbbVie) announced topline results for epcoritamab from the Phase 1/2 trial in patients with relapsed/refractory large B-cell lymphoma (LBCL)Genmab announced its intent to submit a biologics license application (BLA) to the U.S. Food and Drug Administration (U.S. FDA) for epcoritamab for the treatment of patients with relapsed/refractory LBCL, in the second half of 2

  • GlobeNewswire

    Genmab Improves Its 2022 Financial Guidance

    Company Announcement Genmab improves its 2022 financial guidance COPENHAGEN, Denmark; August 8, 2022 – Genmab A/S (Nasdaq: GMAB) announced today that it is improving its 2022 financial guidance published on May 11, 2022. The improved guidance is driven primarily by increased royalty revenue due to higher net sales of DARZALEX and the positive net foreign exchange impact of the strong U.S. Dollar. Genmab expects its 2022 revenue to be in the range of DKK 12,000 – 13,000 million, an increase to th